Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Teligent Inc (TLGT) Ord USD0.01

Sell:$0.52 Buy:$0.52 Change: $0.0775 (13.08%)
NASDAQ:0.44%
Market closed |  Prices as at close on 11 December 2019 | Switch to live prices |
Sell:$0.52
Buy:$0.52
Change: $0.0775 (13.08%)
Market closed |  Prices as at close on 11 December 2019 | Switch to live prices |
Sell:$0.52
Buy:$0.52
Change: $0.0775 (13.08%)
Market closed |  Prices as at close on 11 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Contact details

Address:
105 Lincoln Avenue
BUENA
08310
United States
Telephone:
+1 (609) 6971441
Website:
www.teligent.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TLGT
ISIN:
US87960W1045
Market cap:
$32.85 million
Shares in issue:
53.85 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Gale
    Independent Chairman of the Board
  • Jason Grenfell-Gardner
    President, Chief Executive Officer, Director
  • Damian Finio
    Chief Financial Officer, IR Contact Officer
  • Martin Wilson
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.